French Abivax SA has raised €130m capital led by TCGX to accelerate Phase III testing of its ulcerative colitis candidate obefazimod extend its cashflow.
https://european-biotechnology.com/wp-content/uploads/2024/04/Abivax.jpg500839Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-02-22 21:48:132024-07-12 12:52:31Abivax SA raises €130m to advance obefazimod to Phase III